BLTE: Belite Bio Inc Company Short-Term Debt

Symbol and logo of brand Belite Bio Corp (BLTE)

Belite Bio, Inc (BLTE) enjoys high confidence from the medical community due to its promising retinal therapy methods. The company is implementing AI modeling and automated screening to accelerate molecule discovery, creating revolutionary oral treatments to combat blindness. The short-term debt trend demonstrates the business's current credit load, where 0.00 determines the latest liability valuation metric.

BLTE (Belite Bio, Inc) Company Short-Term Debts history from 04/28/2023 to 10/31/2026

Analytical breakdowns and data insights for company Belite Bio (BLTE)

- current quotes and average value forecast:
Price Chart Belite Bio, Inc|BLTE - Fair Value Consensus
- market capitalization information:
Market Value Belite Bio, Inc.|BLTE - Real Price to Acquire Entire Company
- shareholders' equity book value data:
Book Value per Share Belite Bio|BLTE - Book Capitalization|Market Cap to Net Assets Ratio belitebio.com|BLTE - Aggregate Asset Value
- debt and liquidity data:
Total Debt to Capital Belite Bio, Inc|BLTE - Long-Term Liabilities to Capital|Short-Term Debt to Equity Ratio Belite Bio, Inc.|BLTE - Company Cumulative Debt|Debts to Book Capitalization Belite Bio, Inc.|BLTE - Long-Term Debt|Company Short-Term Debt Belite Bio|Quick Ratio belitebio.com
- net income and valuation multiples indicators:
BLTE - Company Net Income
Basic company analysis:Belite Bio Corp (BLTE)
Manufactured products of Belite Bio Inc

This indicator aggregates the total of all liabilities with a maturity of up to one year, reflecting the pressure on working capital and the risk of liquidity loss. Analyzing current financial obligations allows for an assessment of the ability of Belite Bio, Inc (BLTE) to fund costly developments in ophthalmology, where stability of debt payments is critical for maintaining long-term clinical therapy protocols.

Main competitors

ALC - Company Short-Term Debt|Company Short-Term Loans and Borrowings BLCO (Bausch & Lomb)|Glaukos Corp. (GKOS) - Company Short-Term Debt|Company Current Liabilities Apellis Corp|OCUL (Ocular Therapeutix) - Company Short-Term Debts|Company Short-Term Debts harrowinc.com|Company Current Liabilities VRDN (Viridian Therapeutics, Inc.)|LENZ (LENZ Therapeutics Inc) - Company Short-Term Loans and Borrowings|Company Short-Term Debts OCS (oculis.com)|EyePoint Corp (EYPT) - Short-Term Debt|KOD: Company Current Liabilities|Short-Term Debt Aldeyra Therapeutics|KALA: Company Short-Term Debts|Short-Term Debt Opus Genetics (IRD)|Company Short-Term Debt OKYO Pharma Ltd|Adverum (ADVM) - Short-Term Debt Volume|Company Short-Term Debts OTLK|Company Short-Term Debt CLSD (clearsidebio.com)|Company Short-Term Debts NBY (NovaBay Pharmaceuticals, Inc.)|Kiora Pharmaceuticals Inc. (KPRX) - Short-Term Debt|ALIM - Company Short-Term Debt|EYEN: Company Short-Term Debt|GHSI: Company Short-Term Debts|OCUP - Short-Term Debt Volume|Company Current Liabilities OPT